Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report by Nobutaka Tasaka et al.
a SpringerOpen Journal
Tasaka et al. SpringerPlus 2013, 2:618
http://www.springerplus.com/content/2/1/618CASE STUDY Open AccessTherapeutic effect of dienogest on adenosarcoma
arising from endometriosis: a case report
Nobutaka Tasaka1, Koji Matsumoto1*, Toyomi Satoh1, Takeo Minaguchi1, Mamiko Onuki1, Hiroyuki Ochi1,
Yumiko O Tanaka2, Akiko Sakata3, Masayuki Noguchi3 and Hiroyuki Yoshikawa1Abstract
Dienogest is a novel synthesized progestin used for treatment of endometriosis. This is the first case report
describing a therapeutic effect of dienogest on a gynecologic malignancy. The patient was a 44-year-old woman
with advanced adenosarcoma arising from the endometriosis in the rectovaginal space and infiltrating the left
pelvic wall, left ureter, rectum and vagina. The residual tumor after tumor debulking surgery was resistant to both
chemotherapy and radiotherapy. Dienogest was used as a substitute for medroxyprogesterone acetate because of
the presence of deep vein thrombosis. Based on the RECIST criteria, partial response was obtained with oral
dienogest therapy at six months and the serum CA125 level also decreased from 70 U/ml to 16 U/ml. The tumor
remained stable up to 21 months. Thromboembolism or other adverse effects did not occur during the dienogest
therapy. Dienogest may be useful for the treatment of adenosarcoma arising from endometriosis.
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Müllerian adenosarcoma is a rare tumor characterized by
a benign epithelial component and a sarcomatous stromal
component (Clement et al. 1974; Clement et al. 1990).
These tumors most commonly appear as lesions in the
uterus, derived from the endometrium. To date, how-
ever, several cases of extrauterine adenosarcoma arising
from a background of endometriosis have been reported
(Hines et al. 2002; Liu et al. 2003; Raffaelli et al. 2004;
Huang et al. 2009). Müllerian adenosarcoma is relatively
insensitive to chemotherapy and radiation; thus, an op-
timal therapy for advanced or recurrent tumors remains
to be defined. Histological finding of sarcomatous over-
growth is associated with a highly aggressive clinical
behavior of the tumor.
Medroxyprogesterone acetate (MPA), a synthesized
progestin, has a therapeutic effect on gynecological
malignancies such as adenosarcoma (Hines et al. 2002;
Lee et al. 2010), low-grade endometrial stromal sarcoma
(Amant et al. 2009), and grade 1 endometrial carcinoma
(Ushijima et al. 2007). However, MPA is not used for women* Correspondence: matsumok@mui.biglobe.ne.jp
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significant side-effect of MPA therapy (Kuhl et al. 2006).
We experienced a case of advanced adenosarcoma
that was insensitive to either chemotherapy or radio-
therapy. Since she had asymptomatic deep vein throm-
bosis, dienogest was used as a substitute for MPA for
progesterone therapy.Case presentation
The patient is a 44-year-old G2P2, who had a history of
endometriosis. At 29 years old, she underwent laparoscopic
surgery for endometriosis at a local hospital. At 40 years
old, she was treated with GnRH analog for endometriosis
at another facility. She developed a rapidly growing polyp-
oid mass in the vagina and was referred to our hospital.
Computed tomography (CT) and magnetic resonance
imaging (MRI) showed a polymorphic mass in the pelvis. A
major portion of the mass formed a 5-cm cystic lesion in
the pouch of Douglas, infiltrating to the left acetabular, left
ureter and rectum (Figure 1A). The remainder of the mass
infiltrated through the posterior vaginal fornix, and formed
the polypoid mass occupying the entire vagina (Figure 1B).
She had no metastasis to lymph nodes or distant sites.
The pathological analysis of the biopsy specimen revealed
necrotic tissue. The CA125 was 336.5 U/ml and D-dimern open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
AB
Figure 1 MRI images before the primary surgery. The tumor invaded the left pelvic wall (A; axial fat-saturated T1-weighted image) and the
vagina (B; sagittal T2-weighted image).
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firmed thrombosis of the right soleal vein. Chest CT
demonstrated no evidence of pulmonary embolism. The
patient received anticoagulant therapy with unfractio-
nated heparin followed by warfarin. Thereafter, she was
followed-up by D-dimer assay and Doppler ultrasonog-
raphy. The polypoid mass necrosed and reformed during
the hospital stay.
A total abdominal hysterectomy, bilateral salpingo-
oophrectomy, omentectomy, and tumor debulking pro-
cedures were performed 1 month after the first medical
examination. The uterus was normal-sized and the
endometrium was intact; however, the posterior wall ofthe uterus was adherent to the pelvic mass. The left adnexa
were partially involved to the mass. The right adnexa and
the omentum appeared normal. Sub-optimal cytoreduction
was achieved with the residual tumor remaining adherent
to the left ureter, the rectum, and the left pelvic wall. She
made an uneventful recovery and CA125 fell to 72.7 IU/ml
immediately after the surgery. The final pathologic diag-
nosis was an extrauterine adenosarcoma arising from
the recto-vaginal septum (Figure 2A). This tumor coexisted
with endometriosis. The uterus contained normal endo-
metrium without stromal atypia. Microscopically, the
mitotic rate was 10-12 per 10 high-power fields. The













Figure 2 Tumor Pathology. At the primary surgery, the tumor was diagnosed as an adenosarcoma containing a benign epithelial component
(an endometriotic gland, bottom left) surrounded by an atypical hypercellular stromal component (A; ×200). However, the autopsy following the
rapid tumor regrowth revealed malignant stromal components with sarcomatous overgrowth (D; ×200). At autopsy, the expression levels of
estrogen (E) and progesterone (F) receptors were reduced compared to those at the primary surgery (B and C, respectively).
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of the epithelial and stromal components were positive for
estrogen and progesterone receptors (Figure 2B and 2C).
Postoperatively, the patient underwent adjuvant chemo-
therapy with ifosmide and cisplatin (IFM: 1500mg/m2 day1,
CDDP:20mg/m2 day1-day4; 4 week intervals). After three
cycles of chemotherapy, an MRI revealed that the residual
tumor appeared to be stable disease (SD) by RECIST.
The CA125 was 24.7 IU/ml. Subsequently, she received
cisplatin-based chemoradiotherapy (CCRT: total dose
of 60 Gy irradiation to whole pelvis, CDDP 35mg/m2
weekly; 4 cycles). However, a follow-up MRI after CCRT
demonstrated progressive disease by RECIST and the
CA125 again rose to 70 U/ml. Therefore, the patient
commenced oral DNG therapy at a dose of 2 mg daily.
Written informed consent for DNG therapy was obtained
from the patient. Based on the RECIST criteria, a partialresponse was obtained at six months after initiating oral
DNG treatment (Figure 3). The CA125 gradually fell to 16
U/ml over a six month period (Figure 4) and no adverse
effects occured. Although the tumor was stable for 21
months following dienogest therapy, she had a rapid tumor
relapse 30 months after the surgery. The tumor regrew
into a 10 cm mass, invading directly into the bladder and
the rectum; she died from sepsis 1 month after the tumor
relapse. The autopsy revealed a mixture of benign epithelial
glands and malignant stromal components with sarcoma-
tous overgrowth. In these stromal components, the expres-
sion levels of estrogen and progesterone receptors were
reduced (Figure 2E and 2F).
Discussion
Endometriosis has been reported to give rise to malignant
transformation more frequently in ovarian (5.6%) than at
AB
Figure 3 CT images during dienogest therapy. Based on the RECIST criteria, a partial response was obtained at 6 months after initiating oral
DNG treatment (A: 0 months; B: 6 months) and the tumor was stable up to 21 months.
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In malignant tumors associated with extraovarian endo-
metriosis, adenosarcoma is the second most common
tumor after clear cell adenocarcinoma (Stern et al. 2001).
In this case, adenocarcinoma appeared to arise from endo-
metriosis in the rectovaginal space. The microscopic foci
in the endometrium were found to be contiguous with the
malignant stromal tissue and no other possible primary
tumor site was found.
Progestins are usually used in the treatment of endo-
metriosis, as well as for contraception and hormone
replacement therapy. These compounds interact with
progesterone receptors (PRs) to activate or repress gene
expression in target cells. Synthetic progestines are
structurally classified into two major chemical classes
(Benagiano et al. 2004). Medroxyprogesterone acetate
(MPA) is a 17β-hydroxyprogesterone derivative (C-21
progestogen) that is structurally related to progesterone,while norethisterone (NET) and levonorgestrel (LNG)
are derivatives of 19-northesteron (C-19 nortestosterone)
that are structurally related to testosterone. Of these
compounds, it has been reported that MPA has a thera-
peutic effect on gynecological malignancies such as atypical
endometrial hyperplasia (Ushijima et al. 2007), grade 1
endometrial carcinoma (Ushijima et al. 2007), low-grade
endometrial stromal sarcoma (Amant et al. 2009), and
adenosarcoma (Hines et al. 2002; Lee et al. 2010). However,
thromboembolism is one of the most serious side-effects of
MPA (Kuhl et al. 2006). Vein thromboembolism is found in
9.9% of women with endometrial cancer (Satoh et al. 2008)
and 4.9% of those women with uterine sarcoma (Rodriguez
et al. 2011). Thus, the use of MPA in the treatment of these
malignancies may be limited.
Dienogest (DNG: 17α-cyanomethyl-17β-hydroxyestra-
4,9-dien-3 one) is a novel ‘hybrid progestogen’ that has







Figure 4 CA125 changes through the clinical course.
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antiovulatory activity that reduces serum estrogen level
in vivo (Harada et al. 2009), and direct antiprolirative
and anti-inflammatory effects on endometrial stromal
cells in vitro (Okada et al. 2001). Therefore, DNG has a
therapeutic effect on endometriosis (Harada et al. 2009).
Although DNG has recently been launched for the treat-
ment of endometriosis, DNG also has antiproliferative
effects on estrogen receptosr (ERs)- and/or PR-positive
endometrial and breast cancer cells in vitro, suggesting
potential usefulness in the treatment of ER/PR-positive
malignant tumors (Katsuki et al. 1997; Banno et al. 2012).
DNG has considerable antiandrogenic activity; however,
it has little effect on the metabolic and cardiovascular
systems (Ruan et al. 2012). More importantly, DNG
lacks glucocorticoid activity that can be associated with
an increased risk of venous or arterial thromboembolism
(Ruan et al. 2012; Herkert et al. 2001). To date, DNG-
related thromboembolism has not been reported, even in
long-term use (Momoeda et al. 2009) or high dose therapy
(Schindler et al. 2010). Given its lack of hemostatic action,
DNG appears to be more suitable for the treatment of
endometrial cancer and uterine sarcoma than MPA because
women with these tumors are at an increased risk of ven-
ous thrombosis (Satoh et al. 2008; Rodriguez et al. 2011).
In the presented case, the adenosarcoma underwent
very rapid growth. In addition, this aggressive tumor
was insensitive to either chemotherapy or radiotherapy.
Several case reports have suggested that MPA may be
effective in the treatment of adenosarcoma; however,
MPA was contraindicated in the present case becauseshe had deep vein thrombosis. Therefore, DNG was used
as a substitute for MPA for progesterone therapy. A
successful partial response was obtained at six months
after initiating oral DNG treatment and the tumor was
stable up to 21 months.
The rapid regrowth of the tumor following a long-term
stable status may have been due to the reduction of ER and
PR expression via histological evolution to sarcomatous
overgrowth. In previous reports of adenosarcoma, success-
ful treatment with MPA was demonstrated only for ER-
and PR-positive tumors (Hines et al. 2002; Lee et al. 2010).
Therefore, substantial levels of ER and PR expression
may be necessary to induce the therapeutic effect of DNG,
as well as MPA.
In conclusion, we experienced a case of advanced
adenosarcoma that was treated with DNG. To the best
of our knowledge, this is the first case report describing a
therapeutic effect of DNG on a gynecologic malignancy.
In this case, no adverse effects, including thromboembol-
ism, were observed. DNG may be useful in the treatment
of gynecologic malignancies, such as adenosarcoma,
low-grade endometrial stromal sarcoma and grade 1
endometrial carcinoma, even for women who are at risk
of thromboembolism.
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